ONCOTELIC PROVIDES YE 2022 FINANCIAL RESULTS COMPARED TO YE 2021 PRODUCT DEVELOPMENT INITIATIVES AND CORPORATE UPDATE AGOURA HILLS, Calif., April 17, 2023 (GLOBE NEWSWIRE) -- Oncotelic Therapeutics, Inc. (“Oncotelic”, “We” or the “Company”) (OTCQB:OTLC) is providing a summary of its financial results for the year...

ReAlta Life Sciences, Inc. Partners With Hope for HIE to Improve Neonatal Brain Injury Outcomes and Quality of Life WEST BLOOMFIELD TOWNSHIP, Mich., April 27, 2022 (GLOBE NEWSWIRE) -- ReAlta Life Sciences, Inc. ("ReAlta") a clinical stage, rare disease company addressing life-threatening diseases through...

Neuronascent Announces Third US Patent Issued Covering Therapeutics for Neurodegenerative and Neuropsychiatric Disorders CLARKSVILLE, MD--(Marketwired - January 24, 2017) - Neuronascent's U.S. Patent No. 9,539,261, which issued on January 10, 2017, claims methods of stimulating neurogenesis and/or inhibiting neuronal...